Citations

Clear

395 citation(s) found for "Schneider, R".

Matters of the Heart and Soul: The Mixed Impact of Religiosity and Spirituality on the Cardiovascular Risk Profile Over Time
Neves, Vinicius Vieira , Oliveira, Cesar de, Brewer, LaPrincess C. , Schneider, Ione Jayce Ceola, Steptoe, Andrew

Mayo Clinic

No container title available | September 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.14.26362903 | PMID 42780291 Get It

ABSTRACT Aims Religiosity and spirituality (R/S) are generally associated with a more favourable cardiovascular risk profile, but longitudinal evidence is limited. We examined whether multidimensional R/S predicts its future behavioural and biological components. Methods This prospective cohort study analysed 6,844 adults aged ≥50 (56% women; mean R/S score 2.1; 20% weekly attenders; 81% Christian) from waves 4–7 of the English Longitudinal Study of Ageing (ELSA). Behavioural outcomes included smoking, exercise, alcohol intake, and fruit and vegetable consumption; biological outcomes included blood pressure (BP), haemoglobin A1c (HbA1c), and the inflammatory risk markers C-reactive protein (CRP) and fibrinogen. R/S was assessed with four items from the Santa Clara Strength of Religious Faith Questionnaire. Hierarchical linear and logistic regressions adjusted for age, sex, wealth, education and ethnicity; biomarker models also adjusted for health behaviours and body mass index. Results Greater spirituality ( B =−0.019; 95%CI[−0.036,−0.003]), daily prayer/meditation ( B =−0.017; 95%CI[−0.032,−0.002]), participation in organized religion ( B =−0.017; 95%CI[−0.032,−0.002]), and importance of religious faith ( B =−0.017; 95%CI[−0.033,−0.002]) were independently associated with lower fibrinogen levels. Daily prayer/meditation also independently predicted higher fruit and vegetable intake ( B =0.004; 95%CI[0.000,0.008]). However, frequent attendance (OR=0.846; 95%CI[0.730,0.982]), the significance of faith (OR=0.935; 95%CI[0.879,0.994]), and religious purpose (OR=0.939; 95%CI[0.884,0.997]) independently reduced the odds of meeting exercise recommendations. Similarly, frequent attendance was associated with higher HbA1c ( B =0.002; 95%CI[0.000,0.005]). There were no independent associations with CRP or blood pressure. Conclusion R/S showed mixed prospective associations with the cardiovascular risk profile: favourable for fibrinogen and fruit and vegetable intake, unfavourable for physical activity and HbA1c. LAY SUMMARY We examined whether religious and spiritual involvement was related to later heart-related health behaviours and blood measurements in more than 6,800 English adults aged 50 and over. The associations ran in both directions, and the study cannot show that religion or spirituality causes these changes. Stronger religious and spiritual involvement was associated with lower fibrinogen, a blood protein linked to clotting. Daily prayer or meditation was associated with eating more fruit and vegetables. Regular attendance at religious services was associated with less physical activity and higher blood sugar. GRAPHICAL ABSTRACT
Widespread Loss of Heterozygosity and Endoreduplication in Odontogenic Myxoma
Stojanov, Ivan J. , Dababneh, Melad N., Cracolici, Vincent, Qureshi, Sana, Hattery, Travis , Chen, Mark , Smith, Benjamin F. , O’Neill, Diane, Wolbert, Matthew, Schneider, Keith M., Shurtleff, Sheila, Astbury, Caroline , Geiersbach, Katherine B. , Woo, Sook-Bin, Fritchie, Karen, Weber, Grace E. , Dermawan, Josephine K., Dababneh, Melad , Cracolici, Vincent , O'Neill, Diane H., Schneider, Keith M., Shurtleff, Sheila A., Woo, Sook‐Bin , Fritchie, Karen, Dermawan, Josephine K.

Mayo Clinic

American Journal of Surgical Pathology | September 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pas.0000000000002616 | PMID 42745350 Get It

Odontogenic myxoma (OM) is an uncommon, locally aggressive odontogenic neoplasm with characteristic histologic and clinico-radiographic features but with potential for histologic overlap with other odontogenic and non-odontogenic entities and a non-specific immunoprofile. Widespread loss of heterozygosity (LOH) has been recently described in rare cases of OM. The aim of this study was to determine whether widespread LOH represents a recurrent molecular signature that can be leveraged for clinical decision-making. Allele-specific copy number variation data from chromosomal microarray were generated from 7 OM, comprising a combined prospective and retrospective cohort. Four tumors arose in the mandible and 3 in the maxilla in patients ranging in age from 18 to 94 years (median: 44), with tumor size ranging from 2.2 to 13.0 cm. Variable amounts of fibrous stroma (odontogenic “fibromyxoma”) were present in 4/7 OM, and hypercellularity not typically appreciated in conventional OM was present in 3/7 cases. All OM (7/7) demonstrated widespread LOH, with 5 cases showing a near-haploid/low hypodiploid genomes (multiple monosomies) and 2 cases showing evidence of pseudo-hyperdiploidy due to probable endoreduplication. Both pseudo-hyperdiploid cases were ≥10 cm in size; 1 represented local recurrence. Chromosomes 1 to 3, 6, 9, 11, 13, 15, and 22 demonstrated LOH in ≥75% of cases (chromosomes 1 to 3, 6, and 9 in 100% of cases), while chromosomes 5, 12, 19, and 20 universally retained heterozygosity. Altogether, widespread LOH is a recurrent event in OM and a novel finding in odontogenic pathology, and allele-specific copy number variation analysis can serve as a diagnostic adjunct in challenging cases.
Initial Staging 18 F-FDG PET/CT for Coronary Artery Calcium Scoring to Assess Cardiovascular Risk in Women with Breast Cancer
Fleming, Matthew R. , Tayon, Kevin G., McPherson, Alyssa, Bianco, Sidney M., Lin, Grace , Norton, Nadine , Ray, Jordan , Lin, Grace , Norton, Nadine , Tayon, Kevin G. , Schneider, Artur , Parent, Ephraim E. , Sharma, Akarsh

Mayo Clinic

No container title available | August 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.24.26361275 Get It

Abstract Background. Cardiovascular disease is a leading cause of death among women with breast cancer, and the 2026 ACC/AHA dyslipidemia guideline endorses coronary artery calcium (CAC) scoring to guide statin therapy before cardiotoxic treatment. Breast cancer patients routinely undergo staging 18 F-fluorodeoxyglucose PET/CT, whose low- dose CT visualizes the coronary arteries, thus enabling CAC quantification at no additional cost or radiation. Methods In this single-center retrospective study, consecutive women with newly diagnosed breast cancer undergoing staging 18 F-FDG PET/CT (2009–2021) had semi- automated Agatston CAC scoring performed on the low-dose CT and were stratified by CAC presence (CAC-P) versus absence (CAC-A). We assessed a composite of cardiac diagnostic testing (stress testing, coronary CT angiography, invasive angiography), clinical events, and reclassification of statin eligibility per ACC/AHA guideline thresholds in a prevention-eligible subgroup. Results Among 276 women (mean age 55.5 years; median follow-up 7.1 years), CAC was present in 68 (25%) but was clinically reported in only 5.4%. CAC-P was associated with more cardiac testing (34% vs 12%; age-adjusted hazard ratio 2.75, 95% CI 1.43–5.28) and, though underpowered, with more atherosclerotic events (7.4% vs 1.4%), but not with the all-cause composite. In the prevention-eligible subgroup (n=39), CAC scoring would have changed statin eligibility in 64%, initiating therapy in 62% of CAC-P women and supporting de-prescribing in 67% of CAC-A women. Conclusions CAC can be feasibly quantified from staging PET/CT in women with breast cancer and would frequently reclassify statin eligibility at no additional cost or radiation, yet is rarely reported.
Characterisation of the Novel HLA‐DRB1*10:52 Allele by Next‐Generation Sequencing and Oxford Nanopore Sequencing
Merschman, Jarret , Kreuter, Justin, Millard, Kevin , Schneider, Brittany, Gandhi, Manish J. , Gandhi, Manish , Kreuter, Justin D. , Schneider, Brittany

Mayo Clinic

HLA | August 15, 2026 | Volume: 108 | Issue: 2 | Pages: No page available

10.1111/tan.70921 | PMID 42601336 Get It

ABSTRACT HLA‐DRB1*10:52 is characterised by a single nucleotide substitution in codon 133 in exon 3.
Characterisation of the Novel HLA‐DQA1*01:205N Allele by Next Generation Sequencing and Oxford Nanopore Sequencing
Merschman, Jarret , Kreuter, Justin, Schneider, Brittney, Wakefield, Laurie, Gandhi, Manish J. , Gandhi, Manish , Kreuter, Justin D. , Wakefield, Laurie L.

Mayo Clinic

HLA | August 15, 2026 | Volume: 108 | Issue: 2 | Pages: No page available

10.1111/tan.70917 | PMID 42601337 Get It

ABSTRACT The HLA‐DQA1*01:205N allele is characterised by a nonsense mutation in codon 114 in exon 3.
The vascular contribution to dementia: World Stroke Organization scientific statement
Biessels, Geert Jan , Debette, Stephanie, Elahi, Fanny M, Geranmayeh, Fatemeh, Hansra, Gurpreet , Hughes, Timothy M, Ihara, Masafumi, Isaacs, Jeremy, Jokinen, Hanna, Nott, Alexi, Pendlebury, Sarah, Peters, Ruth, Schneider, Julie, Smith, Colin, Vemuri, Prashanthi, Webb, Alastair J.S. , Wilcock, Donna M, Hainsworth, Atticus H. , Hansra, Gurpreet K , Smith, Eric Edward , Wardlaw, Joanna Marguerite , Webb, Alastair Js , Hainsworth, Atticus H , Biessels, Geert Jan , Debette, Stéphanie , Elahi, Fanny M. , Geranmayeh, Fatemeh , Hughes, Timothy M. , Ihara, Masafumi , Isaacs, Jeremy D. , Jokinen, Hanna , Nott, Alexi , Pendlebury, Sarah Tamsin , Peters, Ruth , Schneider, Julie A. , Vemuri, Prashanthi , Wilcock, Donna M.

Mayo Clinic

International Journal of Stroke | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17474930261470506 | PMID 42454751 Get It

Background: Alzheimer’s disease (AD) and cerebrovascular pathology are the two most common causes of dementia, frequently co-occurring in older people. Community-based neuropathology studies indicate that vascular disease accounts for approximately one-third of the population-attributable risk of dementia, controlling for other pathologies (including AD). The proportion with vascular disease as co-pathology is likely to be higher (50–70%). The most common vascular substrate is cerebral small vessel disease, which includes small artery fibrosis (arteriolosclerosis), vascular amyloid deposits (cerebral amyloid angiopathy), and monogenic forms of small vessel disease, the commonest being Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Post-stroke cognitive impairment following both ischemic stroke and intracerebral hemorrhage also contributes. Aims and Methods: In this World Stroke Organization (WSO) scientific statement, we assembled a multi-disciplinary international group of experts to review the vascular contribution to dementia, encompassing both vascular and neurodegenerative dementia. This statement has been reviewed and approved by the WSO executive. Results: We summarize the epidemiology, neuropathology, cognitive profile, clinical impact and management of vascular disease in dementia and discuss the recent VasCog-2-WSO diagnostic criteria. We consider the substantial overlap with clinical stroke and with AD dementia. We catalog transcriptomic and proteomic studies that have revealed novel candidate molecules ( COL4A1/4A2, HTRA1, TRIM47, FOXF2 ) as possible treatment targets. We appraise imaging-based biomarkers relevant to vascular disease and potential biochemical markers (vascular endothelial growth factor-A, placental growth factor, interleukin-6, matrix metalloproteinase-9, cathepsin-B). We highlight the potential for vascular interventions to treat not only vascular dementia but also the vascular component of neurodegenerative dementia. We review recent clinical trials targeting multiple pathways, including nitric oxide signaling, high blood pressure, the GABAergic system, angiogenic activity, microglial inhibition, PDE3 and PDE5 inhibition, as well as dietary supplementation with omega-3 fatty acids, s-equol and vitamin E. Finally, we consider upcoming opportunities and challenges relevant to vascular disease in dementia. Conclusion: The vascular contribution to dementia is i) substantial, ii) increasingly understood at molecular and mechanistic levels, iii) a source of potential treatment opportunities. Data Access Statement: no original data are presented in this document.
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Gradishar, W J, Moran, Meena S. , Abraham, Jame , Abramson, Vandana, Aft, Rebecca, Agnese, Doreen, Allison, Kimberly H., Anderson, Bethany, Bailey, Janet, Burstein, Harold J. , Chen, Nan , Chew, Helen, Dang, Chau, Giordano, Sharon H., Goetz, Matthew P., Jankowitz, Rachel C., Javid, Sara H., Leitch, A. Marilyn, LYONS, JANICE, McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Rosenberger, Laura H., Santa‐Maria, Cesar A. , Schneider, Bryan P., Smith, Mary Lou , Soliman, Hatem, Speers, Corey, Telli, Melinda L. , Wei, Mei , Wisinski, Kari B., Yellala, Amulya, Schonfeld, Ryan, Telli, Melinda L , Gradishar, William John, Abramson, Vandana G. , Agnese, Doreen Marie , Allison, Kimberly H. , Bailey, Janet E., Chew, Helen K. , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Schneider, Bryan P. , Soliman, Hatem, Speers, Corey , Wisinski, Kari B. , Yeung, Kay T. , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0033 | PMID 42425164 Get It

The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factors such as prior therapy and disease-free interval. Throughout all treatment lines, supportive care, quality of life preservation, toxicity minimization, and clinical trial participation are emphasized as integral components of patient care.
Evaluating MAPT p.A152T as a risk factor for the 3R tauopathy Pick’s disease
Tamvaka, Nicole , Scotton, William J. , Lilley, Meredith T. , Shoai, Maryam , Gavrielatos, Marios , HECKMAN, M, Roemer, Shanu F, Baker, Matthew C, Rademakers, Rosa, Hardy, John , Cook, Casey , Lashley, Tammaryn , Jaunmuktane, Zane, Mok, Kin, Revesz, Tamas, Christopher, Elizabeth, DeTure, Michael, Koga, Shunsuke, Graff-Radford, Neill R, Boeve, Bradley F, Josephs, Keith A. , Petersen, Ronald C, Whitwell, Jennifer , Duara, Ranjan, Lyons, Kelly E, Miller, Bruce, Schlereth, Athena, Spina, Salvatore, Irwin, David J, Wolk, David A, Suh, EunRan, Deerlin, Vivianna M Van, Lee, Edward B, Frosch, Matthew P. , Molina-Porcel, Laura, Aldecoa, Iban, Balasa, Mircea, Borrego-Ecija, Sergi, Sanchez-Valle, Raquel, Gascón‐Bayarri, Jordi , Sanz-Cartagena, Pilar , Huélamo, Rosa Maria de Eugenio, Gefen, Tamar, Castellani, Rudolph J, Rogalskı, Emily , Weıntraub, Sandra , Bieniek, Kevin F, Zhu, Xiongwei, Redding-Ochoa, Javier, Troncoso, Juan C. , Ghetti, Bernardino, Newell, Kathy L. , Jacobsen, Max, Roncaroli, Federico, Jones, Matthew, Richardson, Anna, Snowden, Julie, Allinson, Kieren, Beach, Thomas G, Teich, Andrew F, Flowers, Xena, Heaps, Allison C, Leskinen, Sandra , Keith, Julia , Masellis, Mario, King, Andrew, Sarraj, Safa-Al, Hodges, John R. , Gearing, Marla , Roeber, Sigrun, Attems, Johannes, Boluda, Susana , Seilhean, Danielle, Ber, Isabelle Le, Turbant-Leclere, Sabrina, Mackenzie, Ian R. , Sieben, Anne, Cras, Patrick , Vil, Bart B De, Deyn, P P De, Keene, C Dirk, Latimer, Caitlin S. , Schantz, Aimee, Bird, Thomas D, Haroutunian, Vahram, Purohit, Dushyant, Rissman, Robert, Cykowski, Matthew D. , Wang, Shih-Hsiu J, Ervin, John F. , Nennesmo, Inger , Nagra, Rashed M. , Riehl, James, Kovacs, Gabor G, Neumann, Manuela, Ang, Lee-Cyn, Cunha, Cristina, Blauwendraat, Cornelis , Nalls, Mike A., Singleton, Andrew B, Perrin, Richard J. , Chaffee, Anne M, Scotton, William , Murray, Melissa E , Dickson, Dennis W , Ross, Owen A , Hardy, John , Shoai, Maryam , Lashley, Tammaryn , Heckman, Michael G. , Soto‐Beasley, Alexandra I. , Roemer, Shanu F. , Rademakers, Rosa , Murray, Melissa E. , Dickson, Dennis W. , Rohrer, Jonathan D. , Ross, Owen A. , Valentino, Rebecca R. , Macpherson, Hannah L. , Warner, Thomas T. , Jaunmuktane, Zane , Martínez-Carrasco, Alejandro , Revesz, Tamas, DeTure, Michael , Koga, Shunsuke , Graff‐Radford, Neill R. , Boeve, Bradley F. , Petersen, Ronald C. , Duara, Ranjan, Pahwa, Rajesh , Grinberg, Lea T. , Seeley, William W. , Miller, Bruce L , Spina, Salvatore , Suh, EunRan , Deerlin, Vivianna M. Van , Connors, Theresa R. , Oakley, Derek H. , Molina‐Porcel, Laura , Aldecoa, Ibán , Balasa, Mircea , Borrego‐Écija, Sergi , Sánchez‐Valle, Raquel , Piñol‐Ripoll, Gerard , Gelpí, Ellen , Gefen, Tamar , Castellani, Rudolph J. , Flanagan, Margaret E. , Schneider, Julie A. , Bieniek, Kevin F. , Redding‐Ochoa, Javier , Chang, Koping , Prokop, Stefan , Ghetti, Bernardino, Robinson, Andrew , Roncaroli, Federico , Kobylecki, Christopher , Richardson, Anna, Rowe, James B. , Quaegebeur, Annelies , Allinson, Kieren Simon James, Beach, Thomas G. , Serrano, Geidy E. , Teich, Andrew F. , Black, Sandra E. , Masellis, Mario, Troakes, Claire , Halliday, Glenda M. , Kril, Jillian J. , Kwok, John B. , Piguet, Olivier , Morris, Christopher M. , Thomas, Alan , White, Charles L. , Evers, Bret M. , Mechawar, Naguib , Seilhean, Danielle , Ber, Isabelle Le , Leclère-Turbant, Sabrina, Vil, Bart De , Deyn, Peter Paul De , Keene, C Dirk, Haroutunian, Vahram , Purohit, Dushyant P. , Walker, Jamie M. , Rissman, Robert A. , McLean, Catriona , Graff, Caroline , Riehl, James R. , Giaccone, Giorgio , Neumann, Manuela , Finger, Elizabeth C. , Carvalho, Agostinho , Morris, Huw R. , Singleton, Andrew B, Vitale, Dan , Chaffee, Ann, Wszołek, Zbigniew K.

Mayo Clinic

Brain Communications | July 9, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag266 | PMID 42553595 Get It

Abstract Genetic studies have significantly advanced our understanding of tauopathies, yet the genetic aetiology of Pick’s disease, a rare 3-Repeat tauopathy, remains unclear. The MAPT p.A152T variant has been identified as a risk factor for Alzheimer’s disease and progressive supranuclear palsy, but its role in Pick’s disease is unknown. In this study, we examined the prevalence of MAPT p.A152T in the largest series of neuropathologically confirmed Pick’s disease cases to date (n = 401). Through genotyping, we identified a single mutation carrier in the Pick’s disease cohort (minor allele frequency = 0.12%). We previously reported MAPT p.A152T at a 0.20% frequency in healthy controls (n = 2456), suggesting that it does not associate with 3-Repeat tauopathy risk. To further investigate the effect of the variant on MAPT transcript expression, we used bulk RNA sequencing in Alzheimer’s disease and progressive supranuclear palsy A152T mutation carriers. We did not detect significant differences in 4-Repeat tau levels, though preliminary trends may indicate more nuanced effects that need to be examined with long-read sequencing in a larger series. Overall, our study suggests that MAPT p.A152T does not increase Pick’s disease risk and may instead be linked to 4-Repeat or mixed tau pathologies, warranting further functional investigation.
Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy
Munblit, Daniel , Semple, Malcolm G. , Genuneit, Jon , Ashkenazi‐Hoffnung, Liat , Poland, Gregory A, Bush, Andrew, Boaventura, Viviane, Ulloa‐Gutiérrez, Rolando , Buonsenso, Danilo , Semple, Malcolm G , Genuneit, Jon , Ashkenazi-Hoffnung, Liat , Sultan, Faisal , Putri, Nina Dwi , Apfelbacher, C J , Ulloa-Gutierrez, Rolando , Watson, Hugh R , Oliveira, Carlos R , Reyes, Luis Felipe , Olliaro, Piero , Greenhawt, Matthew , Wilder‐Smith, Annelies , Warner, John O. , Chang, Aileen Y. , Poland, Gregory A. , Boaventura, Viviane Sampaio , Apfelbacher, Christian , Oliveira, Carlos R.

Mayo Clinic

Clinical Infectious Diseases | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag403 | PMID 42554662 Get It

Abstract Unvetted scientific claims about vaccines can spread rapidly and undermine decades of progress in immunization and public trust. A recent non-peer-reviewed analysis, promoted at political hearings, in the documentary “An Inconvenient Study,” and on social media, has been used to suggest that vaccinated children experience higher rates of chronic illness than unvaccinated peers. Despite standard regression models, critical flaws - uncontrolled confounding, exposure misclassification, unequal follow-up, and outcome multiplicity, invalidate causal inference. An independent group of international experts critically appraises this analysis and contrast its claims with the consistent evidence confirming vaccine safety and effectiveness. We also show how poorly designed studies can distort public discourse, amplify misinformation, and fuel vaccine hesitancy. We outline actions to strengthen research integrity, such as transparent data sharing, labeling of non-peer-reviewed content, and evidence-based communication. Safeguarding public health demands that vaccine evidence be methodologically sound, reviewed, and interpreted by qualified experts.